

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

MAR 1 1 2008

Epicor Medical, Inc. c/o Ms. Kathi Guerrant Vice President, Regulatory Affairs and Quality Assurance 1635 Energy Park Drive St. Paul, MN 55108

Re: K040641

Trade Name: Epicor Medical UltraCinch Tissue Ablation Device and Accessories

Regulation Number: 21 CFR 878.4400

Regulation Name: Electrosurgical cutting and coagulation device and accessories

Regulatory Class: II (two) Product Code: OCL, NTB Dated: March 09, 2004 Received: March 10, 2004

Dear Ms. Guerrant:

This letter corrects our substantially equivalent letter of May 5, 2004.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Page 2 - Ms. Kathi Guerrant

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to continue marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Bram D. Zuckerman, M.D.

Director

Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and

Radiological Health

Enclosure

Indications for Use

510(k) Number (if known): <u>Vo40641</u>
Device Name: Epicor Medical UltraCinch Tissue Ablation Device and Accessory Pack
Indications For Use:
The Epicor Medical UltraCinch is intended for the ablation of cardiac tissue during cardiac surgery.
The items in the UltraCinch Accessory Pack are intended for use in the ablation of cardiac tissue during cardiac surgery.
•
Prescription Use X AND/OR Over-The-Counter Use (Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
A La LA
(White D. Coan
(Division Sign-Off) Division of Cardiovascular Devices
510(k) Number 16040641
Page 1 of
Epicor Medical, Inc. CONFIDENTIAL Page B-2

510(k) Notification

This summary of 510(k) safety and effectiveness information is being subr	nitted in
accordance with the requirements of SMDA 1990 and 21 CFR 807.92.	

Date Prepared:

MAY - 5 2004

510(k) number: **V04064**

Applicant Information:

Epicor Medical, Inc.

240 Santa Ana Court Sunnyvale, CA 94085-4512 **Contact Person**

Kathi M. Guerrant

Phone Number: (408) 733-6500 Fax Number: (408) 733-6682

Device Information:

Classification:

Unclassified

Trade Name:

Epicor Medical UltraCinch Tissue Ablation Device and

Accessories

Classification Name:

Ultrasonic Surgical Instruments

Equivalent Device:

The subject device is substantially equivalent in intended use and/or method of operation to the Epicor Medical UltraWand tissue ablation device (K022894), the Medtronic Cardioblate Radiofrequency Ablation System (K013392), the Boston Scientific Cobra RF and Cooled RF Family of Surgical Probes (K013873, K023291), the AFx Microwave Ablation System (K003978, K013946), and the CardioFocus Surgical Lightstic (K011988, K013901).

Intended Use:

The Epicor Medical UltraCinch is intended for the ablation of cardiac tissue during cardiac surgery.

The items in the UltraCinch Accessory Pack are intended for use in the ablation of cardiac tissue during cardiac surgery.

Test Results:

Performance

Results of *in vitro* testing, *in vivo* testing, and human clinical studies demonstrate that the Epicor Medical UltraCinch tissue ablation device and accessories are safe and effective for their intended use.

Biocompatibility

The materials used in the Epicor Medical UltraCinch tissue ablation device and accessories meet the requirements of ISO 10993-1.

Summary: Based on the intended use, product, performance and biocompatibility information provided in this notification, the subject device has been shown to be substantially equivalent to the currently marketed predicate devices.